Works by Barch, David


Results: 5
    1
    2
    3
    4

    A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR.

    Published in:
    Investigational New Drugs, 2020, v. 38, n. 5, p. 1483, doi. 10.1007/s10637-020-00908-3
    By:
    • Cleary, James M.;
    • Calvo, Emiliano;
    • Moreno, Victor;
    • Juric, Dejan;
    • Shapiro, Geoffrey I.;
    • Vanderwal, Carol Ann;
    • Hu, Beibei;
    • Gifford, Maryella;
    • Barch, David;
    • Roberts-Rapp, Lisa;
    • Ansell, Peter J.;
    • Xiong, Hao;
    • Ocampo, Christopher;
    • Tolcher, Anthony W.
    Publication type:
    Article
    5